Efficacy of BAFF inhibition and B-cell depletion in non-obese diabetic mice as a spontaneous model for Sjögren's disease.

Fiche publication

Date publication

août 2024

Journal

RMD open

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DUMORTIER Hélène , Pr GOTTENBERG Jacques-Eric

Tous les auteurs :
Felten R, Foray AP, Schneider P, Marquet C, Pecquet C, Monneaux F, Dumortier H, Sibilia J, Valette F, Chatenoud L, Gottenberg JE

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39209370

Résumé

The therapeutic interest of targeting B-cell activating factor (BAFF) in Sjögren's disease (SjD) can be suspected from the results of two phase II clinical trials but has not been evaluated in an animal model of the disease. We aimed to evaluate the therapeutic efficacy of this strategy on dryness and salivary gland (SG) infiltrates in the NOD mouse model of SjD.